Tumor necrosis factor-alpha G-238A polymorphism and coronary artery disease risk: a meta-analysis of 4,222 patients and 4,832 controls

Xian-Ping Hua¹,*, Xiao-Dong Zhang²,*, Joey SW Kwong³,*, Xian-Tao Zeng⁴, Zhen-Jian Zhang¹
Wan-Lin Wei²

¹Department of Cardiology, Suizhou Hospital, Hubei University of Medicine, Suizhou, Hubei Province, ²Department of Cardiology and 4th Cadres Ward, General Hospital of Beijing Military Command, Beijing, ³Chinese Evidence-Based Medicine Center and Chinese Cochrane Center, West China Hospital, Sichuan University, Chengdu, ⁴Center for Evidence-Based and Translational Medicine, Zhongnan Hospital, Wuhan University, Wuhan, People’s Republic of China

*These authors contributed equally to this work

Background: The aim of the present study was to investigate the association between tumor necrosis factor-alpha (TNF-α) gene G-238A polymorphism and risk of coronary artery disease (CAD) using a meta-analytical approach.

Methods: The PubMed and Embase databases were searched for relevant publications up to January 13, 2015. Four authors (XPH, XZD, XTZ, and ZJJ) independently selected the studies, extracted, and analyzed the data using the Comprehensive Meta-Analysis software. The sensitivity and subgroups analyses were also performed. Either a fixed effects or a random effects model was used to estimate pooled odds ratios (ORs) and their 95% confidence intervals (CIs).

Results: Finally, ten articles including eleven case-control studies involving 4,222 patients and 4,832 controls were yielded. The results indicated no significant association between G-238A polymorphism and CAD risk (A vs G: OR = 1.14, 95% CI = 0.89–1.30; AA vs GG: OR = 1.15, 95% CI = 0.59–2.25; GA vs GG: OR = 1.14, 95% CI = 0.88–1.48; AA vs [GG + GA]: OR = 1.09, 95% CI = 0.56–2.14; [GA + AA] vs GG: OR = 1.11, 95% CI = 0.90–1.38). In the subgroup analyses, similar results were obtained with overall populations. The sensitivity analyses showed that the overall results were robust. No publication bias was detected.

Conclusion: Based on current evidence, we can conclude that TNF-α G-238A polymorphism might not be associated with CAD risk.

Keywords: tumor necrosis factor-alpha, TNF-α, polymorphism, coronary artery disease, coronary heart disease, meta-analysis

Introduction

Tumor necrosis factor-alpha (TNF-α) is an inflammatory mediator that plays important roles in inflammatory and immune responses.¹ Several single-nucleotide polymorphisms (SNPs) have been identified in the TNF-α promoter.² Of these SNPs, conversion from guanine (G) to adenine (A) in the promoter at position-308 (rs1800629) and -238 (rs361525) has been intensively studied for these allelic variations showing functional significance.³⁴ Many studies have identified that the TNF-α G-308A and/or G-238A are associated with many human diseases,⁵⁻⁸ including coronary artery disease (CAD).⁹,¹⁰ Of these diseases, the association between these two polymorphisms and some diseases were identified via a meta-analytical approach, from which inconsistent results can be pooled from original studies and a more precise results can be provided.¹¹ CAD is also named as ischemic heart disease or coronary heart disease, mainly including stable angina pectoris, unstable angina pectoris, and myocardial infarction.¹²,¹³ Serum levels of TNF-α are elevated in patients with CAD and might modify the risk for developing CAD events since it affects endothelial cell hemostatic function.¹⁴ Hence,
we can hypothesize that TNF-α gene polymorphisms might be involved in the CAD susceptibility. In 1998, Herrmann et al performed a case-control study in France and Northern Ireland population, and the results showed that the TNF-α gene G-308A and G-238A polymorphisms were unlikely to contribute to CAD risk in an important way. Since then, many epidemiological studies have been published and inconsistent results have been revealed. The association between TNF-α G-308A polymorphism and CAD risk has been investigated by three published meta-analyses. In contrast, there is no meta-analysis on the association between TNF-α gene G-238A polymorphism and CAD risk until now. Therefore, we conducted this meta-analysis to study the overall correlation between the G-238A polymorphism and CAD susceptibility.

Materials and methods
This meta-analysis was reported according to the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) statement. As meta-analysis is a secondary analysis, ethical approval is not necessary.

Eligibility criteria
According to the PICOS approach, the publication was considered eligible if it met all the following criteria: 1) the patient was clearly diagnosed with CAD, coronary heart disease, ischemic heart disease, stable angina pectoris, unstable angina pectoris, myocardial infarction, or other CAD variants; 2) the exposure was the presence of G-238A polymorphism in the TNF-α gene; 3) the control group was healthy population or volunteers without coronary heart disease manifestations, either from hospital or community; 4) the outcome was the incidence of CAD, either fatal or nonfatal; and 5) the study was used a case-control design. Moreover, the information essential for calculating odds ratios (ORs) and relevant 95% confidence intervals (CIs) should be provided. We chose the most comprehensive report if duplicate publication or overlapped information was identified.

Information sources
The PubMed and Embase databases were searched for relevant publications up to January 13, 2015. Keywords were coronary heart disease, coronary artery disease, ischemic heart disease, angina pectoris, angina, acute coronary syndrome, myocardial infarction, myocardial infarct, polymorphism, and tumor necrosis factor or TNF. References of recent reviews, previous meta-analyses, and eligibility studies were also manually scanned. Table S1 shows the search strategy used for the PubMed.

Data collection
Two authors (XPH and ZJZ) independently retrieved and selected studies for inclusion according to the aforementioned eligibility criteria. Then these two authors extracted the following data from the included studies: the last name of first author and publication year, country of origin and ethnicity, endpoints of CAD, polymorphism, sample size of cases and controls, source of controls, genotype distribution of cases and controls, genotyping method, and Hardy–Weinberg equilibrium (HWE) for control. HWE was tested by χ² test at the 50% significance level. Disagreements were resolved by discussion.

Data analysis
The ORs and corresponding 95% CIs were calculated to summarize the pooled effect sizes for G-238A polymorphism. All possible genetic models, the allelic model (A vs G), dominant model ([AG + AA] vs GG), codominant model (AA vs GG, AG vs GG), and recessive model (AA vs [AG + GG]) were used to estimate the overall relationship.

First, the heterogeneity was quantitatively evaluated using the F statistic. An F value no larger than 25% indicates the absence of heterogeneity, so the fixed effects model was suggested; otherwise, the random effects model was used. The subgroup analysis was performed to investigate the source of heterogeneity and the difference between different ethnicities and HWE. The sensitivity analysis was conducted by sequential omission of individual studies to assess the influence of overall results. The funnel plot and Egger’s test were used to detect the publication bias. All the analyses were conducted using the Comprehensive Meta-Analysis software (version 2.2; Biostat, Englewood, NJ, USA).

Results

Study selection
The flowchart of study selection process is shown in Figure 1. A total of 253 publications were identified initially, and 175 publications were selected for further screening after removing duplicate records. After titles or abstracts were screened, a total of 59 articles preliminarily met the inclusion criteria. Four potential eligible articles were excluded because they were published in Russian and full texts could not be accessed. Two case-control studies identified in one article were considered as independent studies. From four articles with overlapped population, two articles

Therapeutics and Clinical Risk Management downloaded from https://www.dovepress.com/ by 54.70.40.11 on 31-May-2019
For personal use only.
presents more comprehensive information were included. Finally, ten articles with eleven case-control studies were included in this meta-analysis.15,32–40

**Study characteristics**

Eleven case-control studies involving 4,222 cases and 4,832 controls investigated G-238A polymorphism.15,32–40 There were five studies based on Caucasian population15,32,33,35 and six studies concerning Asian population.34,36–40 Three of these studies were out of HWE.37–39 All controls were healthy population, eg, healthy visitors of patients, healthy volunteers, healthy blood donors, or outpatients confirmed negative by cardiac assessment. Table 1 shows the main characteristics of all the included studies.

**Meta-analysis**

Of the eligible eleven case-control studies, one study40 reported significant association; in contrast, the other ten studies demonstrated that the association was nonsignificant (Figure 2). The overall results of five genetic models all identified nonsignificant association between G-238A polymorphism and CAD risk (A vs G: OR =1.08, 95% CI =0.89–1.30, F=34.33%; AA vs GG: OR =1.15, 95% CI =0.59–2.25, F=0%; GA vs GG: OR =1.14, 95% CI =0.88–1.48, F=54.34%; AA vs [GG + GA]: OR =1.09, 95% CI =0.56–2.14, F=0%; [GA + AA] vs GG: OR =1.11, 95% CI =0.90–1.38, F=41.92%).

After being stratified by ethnicity, the results of Asian and Caucasian populations were similar to that of the overall population. The studies in HWE also revealed nonsignificant association. Table 2 shows the overall and subgroup analyses results of G-238A polymorphism and CAD risk. The sensitivity analysis showed that none of the included eleven studies dramatically influenced the pooled results under all the five genetic models (Figure 3).

**Publication bias**

The funnel plots (Figure 4) and Egger's test demonstrated that there was no publication bias in our meta-analysis (P=0.28 for

<table>
<thead>
<tr>
<th>Study</th>
<th>Country (ethnicity)</th>
<th>Disease</th>
<th>Sample (Ca/Co)</th>
<th>Genotype frequency (Ca/Co)</th>
<th>Source of controls</th>
<th>Genotype method</th>
<th>HWE for controls</th>
</tr>
</thead>
<tbody>
<tr>
<td>Herrmann I (1998)15</td>
<td>Northern Ireland (Caucasian)</td>
<td>MI</td>
<td>196/176</td>
<td>168/161 27/15 1/0</td>
<td>Healthy</td>
<td>PCR-SSCP</td>
<td>Yes</td>
</tr>
<tr>
<td>Herrmann F (1998)15</td>
<td>France (Caucasian)</td>
<td>MI</td>
<td>446/531</td>
<td>408/481 36/48 2/2</td>
<td>Healthy</td>
<td>PCR-SSCP</td>
<td>Yes</td>
</tr>
<tr>
<td>Allen et al32</td>
<td>UK (Caucasian)</td>
<td>CAD</td>
<td>180/250</td>
<td>162/220 17/29 1/1</td>
<td>Healthy</td>
<td>PCR-RFLP</td>
<td>Yes</td>
</tr>
<tr>
<td>Szalai et al37</td>
<td>Hungary (Caucasian)</td>
<td>CAD</td>
<td>318/248</td>
<td>287/225 31/23 0/0</td>
<td>Healthy</td>
<td>PCR-RFLP</td>
<td>Yes</td>
</tr>
<tr>
<td>Xiang et al34</td>
<td>People's Republic of China (Asian)</td>
<td>CHD</td>
<td>162/182</td>
<td>154/176 7/6 1/0</td>
<td>Healthy</td>
<td>PCR-RFLP</td>
<td>Yes</td>
</tr>
<tr>
<td>Bennet et al35</td>
<td>Sweden (Caucasian)</td>
<td>MI</td>
<td>1,150/1,468</td>
<td>1,068/1,348 75/119 7/1</td>
<td>Healthy</td>
<td>PCR-RFLP</td>
<td>Yes</td>
</tr>
<tr>
<td>Hou et al36</td>
<td>People's Republic of China (Asian)</td>
<td>CHD</td>
<td>804/905</td>
<td>740/819 63/86 1/0</td>
<td>Healthy</td>
<td>PCR-RFLP</td>
<td>Yes</td>
</tr>
<tr>
<td>Liu et al37</td>
<td>People's Republic of China (Asian)</td>
<td>CHD</td>
<td>276/202</td>
<td>248/191 24/7 4/4</td>
<td>Healthy</td>
<td>PCR-RFLP</td>
<td>No</td>
</tr>
<tr>
<td>Sun et al38</td>
<td>People's Republic of China (Asian)</td>
<td>CHD</td>
<td>73/138</td>
<td>70/129 3/8 0/1</td>
<td>Healthy</td>
<td>PCR-RFLP</td>
<td>No</td>
</tr>
<tr>
<td>Liu et al39</td>
<td>People's Republic of China (Asian)</td>
<td>CAD</td>
<td>420/328</td>
<td>388/311 28/11 4/6</td>
<td>Healthy</td>
<td>PCR-RFLP</td>
<td>No</td>
</tr>
<tr>
<td>Cho et al40</td>
<td>South Korea (Asian)</td>
<td>CAD</td>
<td>197/404</td>
<td>169/371 28/32 0/1</td>
<td>Healthy</td>
<td>PCR-RFLP</td>
<td>Yes</td>
</tr>
</tbody>
</table>

Notes: Herrmann I 1998, the study conducted in Northern Ireland; Herrmann F 1998, the study conducted in France. Abbreviations: Ca, case group; Co, control group; CAD, coronary artery disease; CHD, coronary heart disease; MI, myocardial infarction; HWE, Hardy–Weinberg equilibrium; PCR-SSCP, polymerase chain reaction single-strand conformation polymorphism; PCR–RFLP, polymerase chain reaction–restriction fragment length polymorphism.


### Table 2 Results of overall estimates and subgroup analysis

<table>
<thead>
<tr>
<th>Genetic model</th>
<th>G-238A polymorphism</th>
<th>Studies</th>
<th>OR (95% CI)</th>
<th>Model</th>
<th>P (%)</th>
</tr>
</thead>
<tbody>
<tr>
<td>A vs G</td>
<td></td>
<td>Overall</td>
<td>1.08 (0.89–1.30)</td>
<td>REM</td>
<td>34.33</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Asian</td>
<td>1.21 (0.88–1.68)</td>
<td>REM</td>
<td>42.46</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Caucasian</td>
<td>0.98 (0.77–1.24)</td>
<td>REM</td>
<td>25.48</td>
</tr>
<tr>
<td></td>
<td></td>
<td>HWE (yes)</td>
<td>1.04 (0.84–1.30)</td>
<td>REM</td>
<td>41.47</td>
</tr>
<tr>
<td>AA vs GG</td>
<td></td>
<td>Overall</td>
<td>1.15 (0.59–2.25)</td>
<td>FEM</td>
<td>0</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Asian</td>
<td>0.79 (0.35–1.78)</td>
<td>FEM</td>
<td>0</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Caucasian</td>
<td>2.60 (0.79–8.48)</td>
<td>FEM</td>
<td>0</td>
</tr>
<tr>
<td></td>
<td></td>
<td>HWE (yes)</td>
<td>2.42 (0.89–6.55)</td>
<td>FEM</td>
<td>0</td>
</tr>
<tr>
<td>AG vs GG</td>
<td></td>
<td>Overall</td>
<td>1.14 (0.88–1.48)</td>
<td>REM</td>
<td>54.34</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Asian</td>
<td>1.43 (0.88–2.33)</td>
<td>REM</td>
<td>64.4</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Caucasian</td>
<td>0.91 (0.74–1.11)</td>
<td>FEM</td>
<td>15.9</td>
</tr>
<tr>
<td></td>
<td></td>
<td>HWE (yes)</td>
<td>1.02 (0.80–1.30)</td>
<td>REM</td>
<td>44.86</td>
</tr>
<tr>
<td>AA vs (AG + GG)</td>
<td></td>
<td>Overall</td>
<td>1.09 (0.56–2.14)</td>
<td>FEM</td>
<td>0</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Asian</td>
<td>0.76 (0.34–1.71)</td>
<td>FEM</td>
<td>0</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Caucasian</td>
<td>2.38 (0.73–7.77)</td>
<td>FEM</td>
<td>0</td>
</tr>
<tr>
<td></td>
<td></td>
<td>HWE (yes)</td>
<td>2.26 (0.83–6.12)</td>
<td>FEM</td>
<td>0</td>
</tr>
<tr>
<td>(AG + AA) vs GG</td>
<td></td>
<td>Overall</td>
<td>1.11 (0.90–1.38)</td>
<td>REM</td>
<td>41.92</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Asian</td>
<td>1.31 (0.88–1.94)</td>
<td>REM</td>
<td>53.62</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Caucasian</td>
<td>0.96 (0.77–1.18)</td>
<td>FEM</td>
<td>8.18</td>
</tr>
<tr>
<td></td>
<td></td>
<td>HWE (yes)</td>
<td>1.05 (0.83–1.30)</td>
<td>REM</td>
<td>39.85</td>
</tr>
</tbody>
</table>

**Abbreviations:** OR, odds ratio; CI, confidence interval; REM, random effect model; HWE, Hardy–Weinberg equilibrium; FEM, fixed effect model.

### Discussion

CAD remains the major cause of mortality and morbidity worldwide. Smoking, diabetes, hypertension, obesity, family history, stress, hyperlipidemia, and alcohol abuse were considered the conventional risk factors of CAD; however, these conventional factors can only explain 50% of the total risk factors of CAD cases. Genetic factors might contribute to the other half of the total risk factors, and many polymorphisms are considered to be associated with the onset and development of CAD. Our meta-analysis focused on the TNF-α gene promoter G-238A polymorphism and revealed that this polymorphism was not associated with CAD risk. In the subgroup analyses, similar results with overall population were obtained, and the sensitivity analyses showed that the overall results were robust.

There were ten publications with eleven case-control studies focusing on the G-238A polymorphism and CAD risk in our meta-analysis. According to the result of literature search, our meta-analysis is the first meta-analysis on the G-238A polymorphism. Similar to G-308A polymorphism, our result also revealed a nonsignificant association between G-238A polymorphism and risk of CAD. We also performed subgroup analysis to investigate the effects of ethnicity and HWE. Only Asian and Caucasian populations were adopted. The subgroup analysis revealed no association for Asian population, Caucasian population, and the studies in HWE. Considering the interesting phenomenon of G-308A polymorphism, the G-238A polymorphism included small number of studies and needs further research. In other words, the current result is not the final result.
For this polymorphism, how many new studies should be conducted in the future remains a question. Based on current evidence, we could not judge whether the sample size was sufficient for decisive conclusion. Moreover, whether significant correlation between G-238A polymorphism and risk of CAS exists in other ethnicity, such as Africans or Turks, remains unclear. Also, the polymorphism associated with patients with CAD and concomitant diseases, such as periodontal disease, also needs to be examined in further researches. Moreover, our meta-analysis also provides some clinical implications. We knew that, the personalized drug treatment is involved in the genetic background. Hence, development of a special drug for patients with CAD with G-238A polymorphism is not needed. However, the clinicians should advise their patients with this polymorphism to have peace of mind and not to take this polymorphism as a risk factor in the clinical work. TNF-α G-238A polymorphism might not be considered for the genetic diagnosis of CAD.

Obviously, heterogeneity was large in three genetic models. Mild heterogeneity detected in certain genetic models and subgroup analyses was only partially explained by ethnicity and HWE (Table 2). The heterogeneity is common in meta-analysis of genetic association studies, and we should not ignore it since pooled results may be influenced by heterogeneity. Therefore, the substantial heterogeneity was one limitation of our meta-analysis. Second, as all the included studies were limited within Asians or Caucasians, our conclusion may not be reasonably extrapolated for other ethnic groups. Third, the sample size from eligible studies was not enough. The small sample size might influence the result. Although we tried our best to collect all the relevant studies, certain publications published in languages other than English were not included.

Figure 3: Forest plot of sensitivity analysis by omitting a single study each time of overall population of TNF-α G-238A polymorphism and CAD risk (A vs G model).

Notes: Herrmann I 1998, the study conducted in Northern Ireland; Herrmann F 1998, the study conducted in France.

Abbreviations: TNF-α, tumor necrosis factor-alpha; CAD, coronary artery disease; CI, confidence interval.

Figure 4: Funnel plot of standard error by log odds ratio for detecting publication bias of G-238A polymorphism (A vs G model).
than English or Chinese were excluded because of inac-
tessibility to the full text and/or impenetrability due to lan-
guage barriers. Hence, although the test for publication bias
revealed no publication bias in our meta-analysis, the bias
that originated from publication bias should not be ignored.
Fourth, for lacking original data of gene–gene and gene–
environmental interactions and adjusted conventional risk
factors, we could not further evaluate potential gene–gene
and gene–environmental interactions based on adjusted ORs.
Finally, for lacking appropriate methodological quality tool,11
we did not assess the risk of bias of included studies. Hence,
current results based on unadjusted data may be confounded
to the pooled effect.

Conclusion
In conclusion, there was no evidence suggesting that TNF-α
G-238A polymorphism was associated with the risk of CAD.
The nonsignificant results were without ethnic difference. Due
to the limitations and implications of current meta-analysis,
we suggest that further well-designed studies with large sample
size should be conducted to clarify the association between the
polymorphisms and CAD risk, among which meta-analysis of
genome-wide association studies68 is the best.

Acknowledgments
This study was supported by the National Natural Sci-
ence Foundation of the People’s Republic of China (No
81273971). The funders had no roles in study design, data
collection and analysis, decision to publish, or preparation of
the manuscript.

Disclosure
The authors report no conflicts of interest in this work.

References
Age-related loss of CpG methylation in the tumour necrosis factor pro-
2. Allen RD. Polymorphism of the human TNF-alpha promoter – random
3. Falvo JV, Tsytsykova AV, Goldfeld AE. Transcriptional control of the
4. D’Alfonso S, Richiardi PM. A polymorphic variation in a putative regu-
lation box of the TNFα promoter region. Immunogenetics. 1994;39(2):
150–154.
5. Song GG, Choi SJ, Ji JD, Lee YH. Association between tumor necro-
sis factor-alpha promoter-308 A/G, -238 A/G, interleukin-6-174 G/C
and -572 G/C polymorphisms and periodontal disease: a meta-analysis.
6. Cheng K, Zhao YJ, Liu L, Wan JJ. Tumor necrosis factor-alpha 238 G/A
polymorphism and risk of hepatocellular carcinoma: evidence from a
7. Zhuang L, Ma W, Cai D, Zhong H, Sun Q. Associations between
tumor necrosis factor-alpha polymorphisms and risk of psoriasis: a
8. Li YY. Tumor necrosis factor-alpha g308alpha gene polymorphism and
essential hypertension: a meta-analysis involving 2244 participants.
necrosis factor-alpha G-308A gene polymorphism and coronary heart
127(5):400–405.
10. Pereira TV, Rudnicki M, Franco RF, Pereira AC, Krieger JE. Effect of
the G-308A polymorphism of the tumor necrosis factor alpha gene on
the risk of ischemic heart disease and ischemic stroke: a meta-analysis.
11. Zeng X, Zhang Y, Kwong JS, et al. The methodological quality assess-
ment tools for preclinical and clinical studies, systematic review and
meta-analysis, and clinical practice guideline: a systematic review.
14. Plutjus J. Inflammatory pathways in atherosclerosis and acute coronary
15. Herrmann SM, Ricard S, Nicaud V, et al. Polymorphisms of the
tumour necrosis factor-alpha gene, coronary heart disease and obesity.
polymorphism and risk of coronary heart disease and myocardial infarc-
2012;3(2):84–90.
reporting items for systematic reviews and meta-analyses: the PRISMA
for reporting systematic reviews and meta-analyses of studies that
evaluate health care interventions: explanation and elaboration. BMJ.
2009;6(7).
19. Higgins JP, Thompson SG, Deeks JJ, Altman DG. Measuring inconsis-
20. Patsopoulos NA, Evangelou E, Ioannidis JP. Sensitivity of between-
study heterogeneity in meta-analysis: proposed metrics and empirical
21. Egger M,Davey Smith G, Schneider M, Minder C. Bias in meta-analysis
detected by a simple, graphical test. BMJ. 1997;315(7109):629–634.
ysis: A Computer Program for Meta-Analysis [Computer Program].
23. Yan Y, Weng H, Shen ZH, Wu L, Zeng XT. Association between interleu-
kin-1 gene -590 c/t, -33 c/t, and 70 base-pair polymorphisms and periodonti-
24. Sukhinina TS, Shakhnovich RM, Barsova RM, et al. [Value of allele
gene polymorphism of the inflammation system for prognosis of patients
[with Russian abstract].
25. Kononenk VI, Shevchenko AV, Proko’ ef V, Maksimov VN. [Com-
plex of genotypes of cytokines as a genetic factor of risk of development
of myocardial infarction in European population of Russia men].
26. Shevchenko AV, Golovanova OV, Kononenk VI, et al. [Analysis of
polymorphism of three positions of promoter region of TNF-gene in
patients with ischemic heart disease, unstable angina and myocardial infarc-
27. Sudomoina MA, Sukhinina TS, Barsova RM, et al. [Complex analysis of
association of inflammation genes with myocardial infarction]. Mol


### Supplementary material

#### Table S1 The search strategy of PubMed

<table>
<thead>
<tr>
<th>No</th>
<th>Query results</th>
<th>Results</th>
</tr>
</thead>
<tbody>
<tr>
<td>13</td>
<td>Search polymorphism[Text Word]</td>
<td>229,416</td>
</tr>
<tr>
<td>12</td>
<td>Search (tumor necrosis factor[Text Word]) OR TNF[Text Word]</td>
<td>167,359</td>
</tr>
<tr>
<td>11</td>
<td>Search TNF[Text Word]</td>
<td>113,071</td>
</tr>
<tr>
<td>10</td>
<td>Search tumor necrosis factor[Text Word]</td>
<td>136,792</td>
</tr>
<tr>
<td>9</td>
<td>Search ((((((coronary heart disease[Text Word]) OR ischemic heart disease[Text Word]) OR angina pectori[Text Word]) OR angina[Text Word]) OR acute coronary syndrome[Text Word]) OR myocardial infarction[Text Word]) OR myocardial infarct[Text Word]) OR coronary artery disease[MeSH]</td>
<td>304,794</td>
</tr>
<tr>
<td>8</td>
<td>Search Coronary Artery Disease[MeSH]</td>
<td>37,314</td>
</tr>
<tr>
<td>7</td>
<td>Search myocardial infarct[Text Word]</td>
<td>18,735</td>
</tr>
<tr>
<td>6</td>
<td>Search myocardial infarction[Text Word]</td>
<td>189,875</td>
</tr>
<tr>
<td>5</td>
<td>Search acute coronary syndrome[Text Word]</td>
<td>14,457</td>
</tr>
<tr>
<td>4</td>
<td>Search angina[Text Word]</td>
<td>60,634</td>
</tr>
<tr>
<td>3</td>
<td>Search angina pectori[Text Word]</td>
<td>0</td>
</tr>
<tr>
<td>2</td>
<td>Search ischemic heart disease[Text Word]</td>
<td>20,146</td>
</tr>
<tr>
<td>1</td>
<td>Search coronary heart disease[Text Word]</td>
<td>39,801</td>
</tr>
</tbody>
</table>